Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Sitravatinib
open-in-new
<h2 id="references">References</h2> <ol> <li id="fn:1"><p>Yang Y, Ji N, Cai CY, Wang JQ, Lei ZN, Teng QX, Wu ZX, Cui Q, Pan Y, Chen ZS (July 2020). "Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor". Cancer Communications. 40 (7): 285–300. doi:10.1002/cac2.12040. PMC 7365458. PMID 32525624. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365458" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365458</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li> <li id="fn:2"><p>"Sitravatinib | Mirati Therapeutics, Inc". <a href="http://www.mirati.com/go/mgcd516/" target="_blank">http://www.mirati.com/go/mgcd516/</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li> <li id="fn:3"><p>Clinical trial number NCT02978859 for "MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas" at ClinicalTrials.gov <a href="https://www.clinicaltrials.gov/show/NCT02978859" target="_blank">https://www.clinicaltrials.gov/show/NCT02978859</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li> <li id="fn:4"><p>Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer" at ClinicalTrials.gov <a href="https://www.clinicaltrials.gov/show/NCT02954991" target="_blank">https://www.clinicaltrials.gov/show/NCT02954991</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></p></li> <li id="fn:5"><p>Clinical trial number NCT03015740 for "MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)" at ClinicalTrials.gov <a href="https://www.clinicaltrials.gov/show/NCT03015740" target="_blank">https://www.clinicaltrials.gov/show/NCT03015740</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></p></li> <li id="fn:6"><p>"A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE". 28 February 2022. <a href="https://clinicaltrials.gov/ct2/show/NCT03906071" target="_blank">https://clinicaltrials.gov/ct2/show/NCT03906071</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></p></li> </ol>